GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » 14-Day RSI

Horizon Therapeutics (Horizon Therapeutics) 14-Day RSI : 83.77 (As of May. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-05), Horizon Therapeutics's 14-Day RSI is 83.77.

The industry rank for Horizon Therapeutics's 14-Day RSI or its related term are showing as below:

HZNP's 14-Day RSI is not ranked
in the Drug Manufacturers industry.
Industry Median: 50.87 vs HZNP: 83.77

Competitive Comparison of Horizon Therapeutics's 14-Day RSI

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's 14-Day RSI falls into.



Horizon Therapeutics  (NAS:HZNP) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics  (NAS:HZNP) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Horizon Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (Horizon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman officer: EVP & Chief Medical Officer C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director, officer: President, Chairman and CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher officer: EVP Finance 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin officer: EVP, Technical Operations C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze officer: EVP, Corporate Dev't. C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler officer: EVP, General Counsel C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel director TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000